At a glance
- Originator Rottapharm Madaus
- Developer Rottapharm Biotech; Rottapharm Madaus
- Class Analgesics; Imidazolines; Small molecules
- Mechanism of Action Imidazoline I2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Pain
- No development reported Acute pain; Cancer pain; Neuropathic pain
Most Recent Events
- 30 Nov 2022 CR 4056 is still in phase II clinical development for Pain in Poland and United Kingdom (Rottapharm Biotech pipeline, November 2022)
- 24 Sep 2020 Clinical development for Pain is underway in Poland and United Kingdom (Rottapharm Biotech website, September 2020)
- 15 Jul 2020 Rottapharm Biotech completes four phase I clinical trials (In volunteers), prior to July 2020 (Rottapharm Biotech pipeline, July 2020).